Neurocognitive disorder due to Lewy body disease — clinically familiar as Dementia with Lewy bodies (DLB) — is the second most common neurodegenerative dementia after Alzheimer disease, and the one most likely to be misdiagnosed when a patient is referred for psychosis, depression, or REM sleep behaviour. The DSM-5-TR places it under the major and mild neurocognitive disorder umbrella, with diagnostic criteria that align closely with the McKeith consortium revisions used in neurology. Core features are fluctuating cognition, recurrent well-formed visual hallucinations, REM sleep behaviour disorder, and spontaneous parkinsonism, and clinicians who recognize them early protect their patients from the harm of inappropriate antipsychotic exposure. The bedside questions that matter most are whether cognition fluctuates, whether the patient acts out dreams, and whether visual hallucinations preceded any medication. Get these right, and the rest of the workup — DAT imaging, Polysomnography, and a careful medication review — follows logically. Bottom line: suspect DLB whenever cognitive impairment and parkinsonism appear within a year of each other, and never reach reflexively for a typical antipsychotic.

DLB accounts for roughly 4–7% of dementia diagnoses in specialty memory clinics, though autopsy series suggest the true prevalence in dementia populations is higher because of frequent misclassification as Alzheimer disease.^[1-2] Onset is typically after age 50, with a male predominance and a clinical course of 5–8 years from diagnosis to death.^[1,3]

Burden and demographics

• Estimated prevalence is approximately 0.4% of adults older than 65, rising with age.^[2]
• Mean age of onset is 75 years, with a slight male predominance (roughly 1.5:1).^[1,3]
• DLB and Parkinson disease dementia together account for an estimated 10–15% of all dementia at autopsy.^[1-2]

Comorbidity and risk

• RBD precedes dementia by years to decades in a substantial subset, and phenoconversion to an alpha-synucleinopathy occurs at roughly 6% per year, with cumulative risk reaching ~75% at 12 years.^[4]
• Depression, anxiety, and apathy are frequent prodromal features and may anchor an early psychiatric presentation.^[1,5]
• Orthostatic hypotension and other autonomic features drive disability and fall risk independently of motor severity.^[1,3]
• Family history of dementia or Parkinson disease modestly elevates risk; GBA variants and APOE ε4 are the most consistently identified genetic risk factors.^[6]

The defining lesion is intraneuronal aggregation of misfolded alpha-synuclein into Lewy bodies and Lewy neurites, distributed in brainstem, limbic, and neocortical regions.^[1,7] Concomitant Alzheimer-type pathology (amyloid plaques and tau tangles) is common and accelerates cognitive decline.^[1,7]

Molecular and circuit-level findings

• Alpha-synuclein aggregation begins in autonomic and brainstem nuclei (consistent with the Braak staging hypothesis), then ascends to limbic and neocortical regions, paralleling the emergence of RBD, hallucinations, and dementia.^[7]
• Profound Cholinergic deficit from nucleus basalis of Meynert degeneration is more severe in DLB than in Alzheimer disease and underlies the responsiveness to cholinesterase inhibitors.^[1,8]
• Nigrostriatal dopaminergic loss produces parkinsonism and is the basis of abnormal DAT imaging.^[1,9]
• Reduced cardiac sympathetic innervation produces the characteristic abnormal MIBG myocardial scintigraphy signal.^[1,9]

Genetics and environment

• SNCA, SNCB, GBA, and LRRK2 variants are implicated; GBA heterozygous variants confer the highest individual risk identified to date.^[6]
• APOE ε4 increases risk and accelerates cognitive decline, paralleling its role in Alzheimer disease.^[6]
• Environmental risk factors are less well established than for Parkinson disease, though pesticide exposure and rural living have shown weak associations in epidemiologic studies.^[1]

The DSM-5-TR diagnoses major or mild neurocognitive disorder with Lewy bodies when the general neurocognitive disorder criteria are met and the clinical syndrome includes the core and suggestive features of probable or possible Lewy body disease.^[10] The criteria mirror, with minor wording differences, the McKeith consortium revised criteria used in neurology and movement disorders.^[1]

General requirements

• Evidence of cognitive decline in one or more domains, established by history and objective testing.^[10]
• For major NCD, the impairment interferes with independence in everyday activities; for mild NCD, instrumental activities are preserved with effort.^[10]
• The deficits are not better explained by delirium, another mental disorder, or another medical condition.^[10]

Core clinical features (DSM-5-TR and McKeith 2017):

• Fluctuating cognition with pronounced variations in attention and alertness.^[1,10]
• Recurrent visual hallucinations that are well-formed and detailed.^[1,10]
• REM sleep behaviour disorder, which may precede cognitive decline.^[1,4]
• Spontaneous parkinsonism with onset after cognitive decline.^[1,10]

Suggestive biomarker features

• Reduced striatal dopamine transporter uptake on SPECT or PET imaging.^[1,9]
• Abnormal (low uptake) cardiac MIBG scintigraphy.^[1,9]
• Polysomnographic confirmation of REM sleep without atonia.^[1,4]

Probability levels

• Probable DLB requires two core features, OR one core feature plus at least one indicative biomarker.^[1]
• Possible DLB requires one core feature with no indicative biomarker, OR one or more indicative biomarkers without core features.^[1]

Specifiers (DSM-5-TR)

• Probable versus possible neurocognitive disorder with Lewy bodies.^[10]
• With or without behavioural disturbance (psychotic symptoms, mood disturbance, agitation, apathy, other behavioural symptoms).^[10]
• Severity (mild, moderate, severe) for the major NCD form.^[10]

ICD-11 alignment

• ICD-11 codes dementia due to Lewy body disease under 6D82 with comparable core features.^[11]
• ICD-11 emphasizes the alpha-synucleinopathy spectrum and groups DLB with Parkinson disease dementia under a shared etiologic stem.^[11]

The DLB syndrome typically unfolds with a prodrome of autonomic dysfunction, REM sleep behaviour, hyposmia, depression, or constipation, followed by the cognitive and motor features that bring patients to medical attention.^[1,3] Visual hallucinations and fluctuating attention often dominate the early clinical picture and distinguish DLB from Alzheimer disease.^[1,12]

Cognitive profile

• Prominent deficits in attention, executive function, and visuospatial processing, with relative early sparing of memory.^[1,12]
• Fluctuations may last minutes to days, with episodes of staring, daytime drowsiness, disorganized speech, and reduced responsiveness.^[1,12]
• The MoCA often detects the executive-visuospatial pattern earlier than the MMSE.^[12]

Neuropsychiatric features

• Visual hallucinations are typically well-formed (people, animals, children) and not usually distressing to the patient in early disease.^[1,13]
• Delusional misidentification (Capgras phenomenon) and paranoid delusions are common as disease advances.^[1,13]
• Depression, anxiety, and apathy occur in roughly half of patients across the disease course.^[1,5]

Motor and autonomic features

• Parkinsonism is typically symmetric, with bradykinesia and rigidity; resting tremor is less prominent than in idiopathic Parkinson disease.^[1,3]
• Autonomic dysfunction includes orthostatic hypotension, constipation, urinary urgency, and erectile dysfunction; symptoms may predate dementia by years.^[1,3]
• Falls and unexplained loss of consciousness are common and contribute to morbidity.^[1,3]

Sleep features

• RBD: vivid dream enactment with vocalizations, kicking, or punching, often injurious to the bedpartner.^[4]
• Excessive daytime sleepiness, periodic limb movements, and obstructive sleep apnea are frequent comorbid sleep disorders.^[4]

DLB shares features with several neurodegenerative dementias and with reversible medical syndromes. The clinical task is to distinguish DLB from Alzheimer disease, Parkinson disease dementia, and from delirium superimposed on any baseline dementia.^[1,12] Many patients carry coexisting pathology, so the differential is often a question of which process dominates rather than a binary categorization.^[1,7]

Neurodegenerative differential

• Alzheimer disease: amnestic-predominant onset, less prominent visuospatial deficit, hallucinations later and less well-formed, no early parkinsonism or RBD.^[1,12]
• Parkinson disease dementia: established Parkinson disease for more than one year before cognitive impairment; pathology and biomarker profile overlap with DLB.^[1,3]
• Frontotemporal dementia: prominent personality change or progressive aphasia; visual hallucinations and parkinsonism less typical; younger age of onset.^[12]
• Vascular cognitive impairment: stepwise decline, focal neurologic signs, ischemic lesion burden on imaging.^[12]
• Progressive supranuclear palsy and Corticobasal syndrome: early postural instability, vertical gaze palsy, asymmetric apraxia distinguish these tauopathies from DLB.^[12]
• Creutzfeldt-Jakob disease: rapid progression (weeks to months), myoclonus, characteristic EEG and MRI changes.^[12]

Medical and psychiatric mimics

• Delirium: acute onset, identifiable precipitant, marked attention deficit; DLB fluctuations are not equivalent to delirium and may co-occur.^[1]
• Charles Bonnet syndrome: complex visual hallucinations in the visually impaired without other neurologic or cognitive features.^[13]
• Late-onset primary psychotic disorder: rare; absent the cognitive, motor, and sleep features of DLB.^[13]
• Medication-induced parkinsonism and hallucinations: review dopamine antagonists, anticholinergics, opioids, and benzodiazepines.^[1,14]
• Thyroid disease, vitamin B12 deficiency, neurosyphilis, HIV-associated cognitive disorder, and limbic encephalitis: reversible or treatable mimics that should be screened.^[12]

Diagnosis is clinical, supported by collateral history, targeted cognitive testing, and selective use of biomarker imaging when the diagnosis is uncertain.^[1,12] A structured assessment minimizes the most common error in DLB — premature labeling as Alzheimer disease or a primary psychotic disorder.^[1,13]

Interview and history

• Collateral history from a bedpartner or caregiver is essential, particularly for fluctuations, hallucinations, and dream enactment.^[1,4]
• Document time course of cognitive, motor, autonomic, and sleep features, with attention to the one-year rule for DLB versus Parkinson disease dementia.^[1,3]
• Review every medication, including over-the-counter anticholinergics and recently introduced dopamine antagonists.^[1,14]

Mandatory history elements

• Fluctuations: episodes of staring, daytime drowsiness, transient confusion, or fluctuating coherence.^[1,12]
• Visual hallucinations: content, distress, insight, frequency.^[1,13]
• RBD: vocalization, dream enactment, injury to self or bedpartner.^[4]
• Falls, syncope, orthostatic symptoms, urinary symptoms, constipation, hyposmia.^[1,3]
• Mood, anxiety, apathy, suicidal ideation.^[5]

Physical and neurologic exam

• Parkinsonian signs: bradykinesia, rigidity, postural instability, tremor.^[1,3]
• Orthostatic vitals after 3 minutes of standing.^[1,3]
• Gait and balance assessment; functional reach or pull test.^[3]
• Screen for focal signs that suggest vascular or structural disease.^[12]

Cognitive screening and rating scales

• Montreal Cognitive Assessment (MoCA) is more sensitive than the MMSE for executive-visuospatial deficits.^[12]
• Pentagon copy, clock drawing, and trail-making tests highlight visuospatial and executive impairment.^[12]
• The Neuropsychiatric Inventory quantifies hallucinations, delusions, depression, agitation, and apathy.^[13]
• The Mayo Fluctuations Composite Scale helps operationalize fluctuating cognition.^[1,12]

Labs and routine workup

• CBC, BMP, LFTs, TSH, B12, HbA1c, urinalysis to screen reversible mimics.^[12]
• Targeted testing as indicated: HIV, RPR, vitamin D, ammonia, ANA, ceruloplasmin, paraneoplastic antibodies in atypical presentations.^[12]
• Structural neuroimaging (MRI preferred over CT) to assess vascular burden, atrophy pattern, and rule out structural lesions.^[12]

Biomarker imaging when diagnosis is uncertain:

• DAT-SPECT (123I-FP-CIT, ioflupane) shows reduced striatal uptake in DLB and is normal in Alzheimer disease; sensitivity is approximately 78% and specificity approximately 90% for probable DLB.^[1,9]
• Cardiac MIBG scintigraphy shows reduced uptake reflecting postganglionic sympathetic denervation and is highly specific for Lewy body disease.^[1,9]
• Polysomnography confirms REM sleep without atonia when RBD is suspected.^[4]
• MRI typically shows relative preservation of the medial temporal lobes compared with Alzheimer disease, though this is supportive rather than diagnostic.^[1,12]

What NOT to order

• Routine CSF amyloid/tau is not diagnostic of DLB and should not be the test of first choice; reserve for differentiating Alzheimer-predominant from Lewy-predominant pathology in atypical cases.^[12]
• Routine genetic testing is not indicated outside research or strongly suggestive family history.^[6]
• Whole-body PET screening, paraneoplastic panels, and infectious workup should be ordered only when the history or exam suggests them.^[12]

Management of DLB is multimodal, targeting cognitive, neuropsychiatric, motor, autonomic, and sleep symptoms. Pharmacotherapy must be individualized given pronounced sensitivity to many psychotropic and dopaminergic agents.^[1,8,14,16] Cognitive symptoms Cholinesterase inhibitors (rivastigmine, donepezil) are first-line for cognitive and neuropsychiatric symptoms in DLB. Evidence is strongest for rivastigmine, which has shown improvement in attention, executive function, and visual hallucinations in randomized trials. Treatment effects are often more pronounced than in Alzheimer disease.^[8,15-16] Memantine may be added or used as an alternative, with modest benefit on global clinical impression.^[17] Neuropsychiatric symptoms Visual hallucinations and delusions often respond to cholinesterase inhibitor optimization before considering antipsychotics. When antipsychotics are required for severe, distressing, or dangerous symptoms, quetiapine or clozapine are preferred at the lowest effective dose; clozapine has the strongest evidence but requires haematologic monitoring. Typical antipsychotics and high-potency atypicals (haloperidol, risperidone, olanzapine) should be avoided due to risk of severe neuroleptic sensitivity reactions, including rigidity, autonomic instability, and death.^[14,16,18] Depression and anxiety can be treated with SSRIs, avoiding agents with strong anticholinergic activity (e.g., paroxetine).^[5,16] Motor symptoms Parkinsonism responds variably to levodopa, with less robust improvement than in Parkinson disease and a higher risk of provoking or worsening hallucinations and confusion. Use the lowest effective dose, titrate slowly, and avoid dopamine agonists, amantadine, and anticholinergics where possible.^[16,19] Sleep and autonomic symptoms REM sleep behaviour disorder is treated with melatonin (3–12 mg at night) as first-line; clonazepam is an alternative but may worsen cognition, gait, and daytime sedation. Orthostatic hypotension is managed with non-pharmacological measures (hydration, compression stockings, head-of-bed elevation) and, if needed, midodrine or fludrocortisone, balanced against supine hypertension risk. Constipation, urinary symptoms, and excessive daytime sleepiness should be assessed and treated.^[4,16,20] Non-pharmacological Cognitive rehabilitation, structured routines, caregiver education, fall-prevention programmes, and physiotherapy/occupational therapy are core elements. Early advance care planning is recommended given the progressive course.^[16,21]

EVIDENCE_TABLE

| Intervention | Indication | Effect size | Certainty | Source |

| Rivastigmine | Cognition, hallucinations | Moderate (NPI ↓ ~6 pts) | Moderate | McKeith 2000; Cochrane 2015 ^[8,15] |

| Donepezil | Cognition, global function | Small-moderate | Moderate | Mori 2012 ^[16] |

| Memantine | Global clinical impression | Small | Low-moderate | Aarsland 2009 ^[17] |

| Quetiapine | Psychosis (low dose) | Small; safety profile favorable | Low | Observational; expert consensus ^[16,18] |

| Clozapine | Refractory psychosis | Moderate | Low-moderate | Extrapolated from PDD trials ^[18] |

| Levodopa | Parkinsonism | Small-moderate; variable | Low | Open-label; observational ^[19] |

| Melatonin | RBD | Moderate; symptom reduction | Moderate | Aurora 2010; McGrane 2015 ^[20] |

| Typical/high-potency antipsychotics | Avoid | Harm: severe neuroleptic sensitivity | High (harm) | McKeith 1992; consensus ^[14,16] | END_TABLE

Severe neuroleptic sensitivity reactions occur in roughly 30–50% of DLB patients exposed to typical antipsychotics and high-potency atypicals, with up to a 2–3-fold increase in mortality. Reactions include rigidity, autonomic instability, confusion, and irreversible parkinsonism; they can occur on first exposure and at low doses.^[14,16] Cholinesterase inhibitors commonly cause nausea, diarrhoea, bradycardia, syncope, and falls; baseline ECG and cautious titration are recommended, especially in patients with conduction disease.^[8,15-16] Levodopa may worsen psychosis; dopamine agonists, anticholinergics, and benzodiazepines should generally be avoided. Trial evidence is limited by small sample sizes, heterogeneous diagnostic criteria across studies, and frequent exclusion of older or comorbid patients, reducing generalizability.^[16]

Older adults (≥75 years) constitute the majority of DLB patients; polypharmacy and comorbidity (cardiovascular disease, frailty, falls) heighten the risk of adverse drug effects. Start medications at low doses and titrate slowly. Women may present with more affective symptoms and fewer overt parkinsonian features, contributing to diagnostic delay.^[2,5,22] Younger-onset cases (<65 years) are uncommon and warrant evaluation for genetic contributions (e.g., GBA, SNCA, APOE ε4) and reversible causes.^[6,16] Patients with comorbid Alzheimer pathology (mixed DLB/AD) may respond less robustly to cholinesterase inhibitors and progress more rapidly. Hospitalized DLB patients are at particularly high risk for delirium, neuroleptic exposure, and falls; care plans should explicitly flag DLB diagnosis and antipsychotic precautions.^[16]

DLB is progressive. Median survival from diagnosis is approximately 5–7 years, shorter than Alzheimer disease, though wide variation exists. Predictors of faster decline include older age at onset, prominent parkinsonism, severe autonomic dysfunction, early hallucinations, and mixed pathology. Cognitive fluctuations, falls, aspiration pneumonia, and complications of immobility are common causes of morbidity and death.^[1,23] Quality of life is affected by caregiver burden, which is typically higher in DLB than AD due to behavioural and motor symptoms; caregiver support and respite are integral to management.^[24]

The boundary between DLB and Parkinson disease dementia (PDD) remains contested. The current “one-year rule”—DLB if dementia precedes or coincides with parkinsonism within 12 months, PDD if dementia follows established Parkinson disease—is pragmatic but biologically arbitrary; both share Lewy-related pathology and many authors advocate viewing them as a single Lewy body disease spectrum.^[1,3,25] The role of comorbid Alzheimer pathology in shaping presentation and response to therapy is incompletely understood and may influence biomarker-based diagnosis.^[16,26] Whether prodromal DLB (mild cognitive impairment with Lewy body features, isolated RBD) should trigger disease-modifying intervention is an active area of research, with several alpha-synuclein–targeted agents in trials.^[27] Finally, equitable access to confirmatory imaging (DAT-SPECT, MIBG) and specialist diagnosis remains a persistent global health gap.^[16]

1. Core clinical features of DLB are fluctuating cognition, recurrent well-formed visual hallucinations, REM sleep behaviour disorder, and parkinsonism (mnemonic: F-P-R-H).^[1]
2. Probable DLB requires dementia plus ≥2 core features, or ≥1 core feature plus ≥1 indicative biomarker (DAT-SPECT, MIBG scintigraphy, polysomnography-confirmed RBD).^[1]
3. The “one-year rule” distinguishes DLB (dementia before or within 12 months of parkinsonism) from Parkinson disease dementia.^[1,3]
4. Severe neuroleptic sensitivity occurs in ~30–50% of DLB patients exposed to typical antipsychotics or high-potency atypicals; haloperidol and risperidone should be avoided.^[14,16]
5. Rivastigmine is first-line for cognitive symptoms and visual hallucinations in DLB; effect sizes are often larger than in Alzheimer disease.^[8,15]
6. Quetiapine (low dose) and clozapine are the preferred antipsychotics if pharmacotherapy is unavoidable for severe psychosis.^[16,18]
7. Melatonin is first-line for REM sleep behaviour disorder in DLB; clonazepam is an alternative but may worsen cognition.^[20]
8. Parkinsonism in DLB is typically symmetric with prominent postural instability and gait impairment; tremor is less common than in PD.^[1,3]
9. DAT-SPECT shows reduced striatal dopamine transporter uptake; MIBG scintigraphy shows reduced cardiac sympathetic innervation—both are indicative biomarkers.^[1,9]
10. Median survival from diagnosis is approximately 5–7 years, shorter than Alzheimer disease.^[1,23]
11. Caregiver burden in DLB is typically higher than in AD due to behavioural and motor symptoms; support is part of management.^[24]
12. Avoid anticholinergics (oxybutynin, paroxetine, tricyclics) in DLB—they worsen cognition and psychosis.^[5,16]

This article is intended for educational purposes for clinicians and trainees and does not constitute individual medical advice. Treatment decisions must be made by a qualified clinician with knowledge of the patient's clinical context, comorbidities, and local regulatory and prescribing environment. The authors report no conflicts of interest relevant to this article.